AU2023262166A1 - Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate - Google Patents

Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate Download PDF

Info

Publication number
AU2023262166A1
AU2023262166A1 AU2023262166A AU2023262166A AU2023262166A1 AU 2023262166 A1 AU2023262166 A1 AU 2023262166A1 AU 2023262166 A AU2023262166 A AU 2023262166A AU 2023262166 A AU2023262166 A AU 2023262166A AU 2023262166 A1 AU2023262166 A1 AU 2023262166A1
Authority
AU
Australia
Prior art keywords
solution
pharmaceutical composition
formula
organic solvent
filler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023262166A
Other languages
English (en)
Inventor
Hao Hou
Laura JERKE
Michael Kammerer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Publication of AU2023262166A1 publication Critical patent/AU2023262166A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2023262166A 2022-04-28 2023-04-27 Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate Pending AU2023262166A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22170407.5 2022-04-28
EP22170407 2022-04-28
PCT/EP2023/061060 WO2023209062A1 (en) 2022-04-28 2023-04-27 Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate

Publications (1)

Publication Number Publication Date
AU2023262166A1 true AU2023262166A1 (en) 2024-10-17

Family

ID=81392840

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023262166A Pending AU2023262166A1 (en) 2022-04-28 2023-04-27 Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate

Country Status (11)

Country Link
US (1) US20250282775A1 (https=)
EP (1) EP4514792A1 (https=)
JP (1) JP2025512583A (https=)
KR (1) KR20250006222A (https=)
CN (1) CN119156386A (https=)
AU (1) AU2023262166A1 (https=)
CA (1) CA3255956A1 (https=)
IL (1) IL316096A (https=)
MX (1) MX2024013116A (https=)
TW (1) TW202400141A (https=)
WO (1) WO2023209062A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202602868A (zh) * 2024-04-15 2026-01-16 瑞士商諾華公司 瑞波西利的藥物組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI874834B (zh) 2014-12-18 2025-03-01 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
CR20200621A (es) 2018-06-21 2021-02-03 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso

Also Published As

Publication number Publication date
MX2024013116A (es) 2024-11-08
WO2023209062A1 (en) 2023-11-02
CN119156386A (zh) 2024-12-17
JP2025512583A (ja) 2025-04-17
KR20250006222A (ko) 2025-01-10
IL316096A (en) 2024-12-01
US20250282775A1 (en) 2025-09-11
TW202400141A (zh) 2024-01-01
EP4514792A1 (en) 2025-03-05
CA3255956A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
KR101830147B1 (ko) 벤다무스틴의 경구 투약 형태 및 그것의 치료 용도
EP1574215B1 (en) Solid drug for oral use
KR20110033852A (ko) 도파민 수용체 리간드를 함유하는 약학적 제형
AU2025275308A1 (en) Immediate release formulations of d-lysergic acid diethylamide for therapeutic applications
JP2024508737A (ja) 疾患を治療するための方法および医薬組成物
EP2514422B1 (en) Elution stabilized teneligliptin preparation
AU2024204906A1 (en) Acalabrutinib maleate dosage forms
EP3354283B1 (en) Pharmaceutical capsule composition comprising silodosin
US20250282775A1 (en) Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
US9981040B2 (en) Capsule formulation
CN109001353B (zh) 富马酸喹硫平片剂药物组合物和制法
HK40115442A (zh) 3-((1r，3r)-1-(2，6-二氟-4-((1-(3-氟丙基)氮杂环丁烷-3-基)氨基)苯基)-3-甲基-1，3，4，9-四氢-2h-吡啶并[3，4-b]吲哚-2-基)-2，2-二氟丙-1-醇酒石酸盐的固体形式
US11648242B2 (en) Pharmaceutical composition comprising pimavanserin, process of preparation and use thereof
US20250064798A1 (en) Vilazodone composition, pharmaceutical preparation thereof, preparation therefor, and use thereof
JP2024532191A (ja) Ｖｍａｔ２阻害剤についてのスクリーニングの方法
JP7084950B2 (ja) 非拍動性持続放出ベタヒスチン経口固形組成物
WO2024225996A1 (en) A new pharmaceutical tablet composition comprising eltrombopag olamine
WO2019070845A1 (en) COMPOSITIONS AND METHODS OF USING CIS-4- [2 - {[(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO} -8- (2,4,6-TRICHLOROANILINO) -9H-PURINE-9 yl] -1-methylcyclohexane-1-carboxamide
CN104644643A (zh) 一种复方氢氯噻嗪晶体化合物缬沙坦药物组合物